Drugs / Uproleselan
Uproleselan
also known as
GMI-1271 · [14C]-Uproleselan · ABI-701 · E-selectin antagonist gmi-1271 · GMI-1271 FREE ACID · GMI-1271 SODIUM · UPROLESELAN SODIUM
Small molecule targets SELE via inhibition
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05146739 | Oct 2023 → Mar 2025 overdue | mixed phenotype acute leukemia, myelodysplastic syndrome, myeloid leukemia associated with down syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05569512 | Oct 2022 → Oct 2023 | acute myeloid leukemia, childhood malignant neoplasm | Malika Kapadia | Terminated | No outcome recorded |
| Phase 1 | NCT04964505 | Jul 2021 → Oct 2024 | acute myeloid leukemia | Brian Jonas | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04839341 | Feb 2021 → Jun 2024 | acute myeloid leukemia | Apollomics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03606447 | Aug → Sep 2018 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02811822 | Jun 2016 → Apr 2019 | plasma cell myeloma | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02703051 | Nov 2015 → Aug 2016 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02271113 | Oct 2014 → Mar 2016 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02168595 | Jun → Aug 2014 | — | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05057221 | Nov 2021 → Mar 2022 | pneumonia | Lena Napolitano, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT04848974 | Jun 2021 → Oct 2024 | acute myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02744833 | Jul → Nov 2016 | venous thromboembolism | GlycoMimetics Incorporated | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02306291 | Mar 2015 → Dec 2017 | acute myeloid leukemia | GlycoMimetics Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04682405 | May 2021 → Nov 2022 | plasma cell myeloma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03701308 | Mar 2019 → Oct 2024 overdue | acute myeloid leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05054543 | Nov 2021 → Aug 2024 | acute myeloid leukemia | Apollomics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT03616470 | Oct 2018 → Mar 2024 | acute myeloid leukemia | GlycoMimetics Incorporated | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-12-20 | Apollomics Inc. | Results Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia apollomicsinc.com ↗
The trial did not demonstrate favorable benefit for uproleselan. |
| 2022-12-22 | Apollomics Inc. | Regulatory Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia apollomicsinc.com ↗
Foster City, CA, and Hangzhou, China, September 27, 2020 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced APL-106 (uproleselan) has received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). |
| 2022-12-22 | Apollomics Inc. | Regulatory APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia apollomicsinc.com ↗
today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML). |
All press releases naming this drug 7 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uproleselan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05146739 ↗ |
| Known as | [14C]-Uproleselan | “the radiolabelled test medicine \[14C\]-Uproleselan (GMI-1271) is taken up, broken down and removed from the body” NCT03606447 ↗ |
| Known as | ABI-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989971 ↗ |
| Known as | E-selectin antagonist gmi-1271 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989971 ↗ |
| Known as | GMI-1271 | “more specifically, rivipansel (GMI-1070) and uproleselan (GMI-1271), may be used to treat COVID-19 patients with respiratory symptoms that may lead to ARDS” NCT05057221 ↗9“Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia” NCT03616470 ↗ “the radiolabelled test medicine \[14C\]-Uproleselan (GMI-1271) is taken up, broken down and removed from the body” NCT03606447 ↗ “Uproleselan (GMI-1271)” NCT04682405 ↗ |
| Known as | GMI-1271 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989971 ↗ |
| Known as | GMI-1271 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989971 ↗ |
| Known as | UPROLESELAN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989971 ↗ |
| Action | Inhibit | “Selectin E antagonist” CHEMBL3989971 ↗1“E-selectin antagonist” NCT02168595 ↗ |
| Modality | Other / unclassified | “GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist” NCT02168595 ↗ |
| Route | Intravenous | “single ascending IV dose study” NCT02168595 ↗ |
| Target | SELE | “Selectin E antagonist” CHEMBL3989971 ↗ |